Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
about
Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise reviewKASL clinical practice guidelines: management of hepatitis CProfile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infectionDrug-Drug Interactions Between Direct-Acting Antivirals and Psychoactive MedicationsDosing Recommendations for Concomitant Medications During 3D Anti-HCV TherapyChallenges in treating patients with inflammatory bowel disease and concurrent viral hepatitis infection.Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyAssessment of drug-drug interactions between daclatasvir and methadone or buprenorphine-naloxone.Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-RitonavirPopulation Pharmacokinetics of Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir, and Ribavirin in Patients with Hepatitis C Virus Genotype 1 Infection: Combined Analysis from 9 Phase 1b/2 StudiesDrug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without DasabuvirPharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers.Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and RilpivirinePharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIVDrug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus LamivudineRandomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.Ritonavir-boosted protease inhibitor based therapy: a new strategy in chronic hepatitis C therapy.Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.Drug interactions of hepatitis C direct-acting antivirals in the HIV-infected person.What does the pharmacological future of treating chronic hepatitis C look like?Real world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions.Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction Between Clopidogrel and Dasabuvir.Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials.Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.Clinical Pharmacokinetics of Ombitasvir.Clinical Pharmacokinetics of Paritaprevir.Clinical Pharmacokinetics of Dasabuvir.Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing AgentsDose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
P2860
Q26747705-EC667D43-D8E7-4525-926C-2717A7B09EE8Q26752471-A456D93A-FC22-424B-AD0A-222FBB6791DDQ26775825-C2F653A4-EB3D-4B38-B4F3-2E1DCC2F069DQ28069639-A0571210-6A91-400A-B117-BB3B9E488608Q28080752-5F602EA0-45CB-4105-A2FC-CE617940B899Q30244767-AC8E2E66-FBC7-4250-8754-429DA286A888Q31168033-CD7B6220-C23C-481F-857A-C4956A27C9FFQ35960681-B75ECDA8-0A47-4375-94E7-E2670A0C66D6Q36438920-1EEEAFE7-80A2-486C-BC08-CB67C82AA23CQ36445132-F58861B9-62EE-4BD5-8A57-806D0A629FE1Q36571969-CE426B93-7F3A-4189-8ABF-8BE5AEC756C9Q36806650-5E47E78F-44A6-4F77-9F24-0E6EF8589C14Q36888008-21AF62C5-11DF-49C9-ACF9-DF75A6710020Q37055231-C455BBB0-9BC4-4FF1-A21A-5C6F6D8443DCQ37067118-C2BD654A-7ECC-4EFE-BD23-4C57CEBF9D0CQ37287684-3D7D5318-63D5-4E71-B638-1CA9872D2585Q37309080-23AC77AA-C69C-4EA3-8B89-6267BDF67ABDQ38393581-A8643474-F5B2-4B92-8973-1A73E6FB23C9Q38407722-145EC85F-A662-4E74-B5D5-5B08EE1E3A1BQ38435908-86B79269-00F9-4053-9CCE-300468F55D9DQ38544578-98F8074E-FFBC-441D-8CF0-F5D6B67D1341Q38569681-98E4EB2B-FF3C-4B47-BF60-FDBD325AC990Q38620762-02002391-3BD3-4A21-BA71-99703892454EQ38684505-9E3C05D0-EBF4-49BE-8C12-C03C4016ACE2Q38703524-54F98CAD-8CB4-4908-B7B7-234921AF0369Q38824198-0A264CEB-57EE-4F79-945A-0DAEE38FC40EQ38836056-2DBAE984-D79D-497A-8696-F3A5CB508BF8Q38837174-02D1ECE7-3291-4915-9681-4308C7C5458BQ38880996-5D1A1B4F-77BD-4043-A4AC-4D958010F119Q38893128-D59D88BC-7EB0-4299-BF81-86D944339766Q38927209-2AEB2441-38B3-4D3B-A66E-F099B510CEA4Q38929010-60A20ABF-D384-4DDB-886D-0A0AEB5DB81BQ38933872-B200A7AB-3E35-4C06-89E1-FD6D368B913BQ39147495-365C2D2A-6545-4666-97DD-9B8AF0774F2BQ39150134-D9FAC9A6-E4DF-4D78-8D3F-8934B47A5151Q39160612-897A2279-6A6F-4054-AC6B-5940942D179AQ39357557-8B48092A-4092-4206-B642-6E57BC40A238Q39675766-2D292A2A-ED53-460E-9DBC-9194069425C1Q39862666-C570E75A-D605-46C7-B94F-38D893451AFEQ39900651-15E89032-D7A8-4980-9C1B-CCF12996DA7C
P2860
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Drug-drug interaction profile ...... ir, ombitasvir, and dasabuvir.
@en
type
label
Drug-drug interaction profile ...... ir, ombitasvir, and dasabuvir.
@en
prefLabel
Drug-drug interaction profile ...... ir, ombitasvir, and dasabuvir.
@en
P2093
P921
P1476
Drug-drug interaction profile ...... ir, ombitasvir, and dasabuvir.
@en
P2093
Akshanth R Polepally
Amit Khatri
Eoin P Coakley
Haoyu Wang
Jiuhong Zha
Prajakta S Badri
Rajeev M Menon
Sandeep Dutta
Thomas J Podsadecki
P356
10.1016/J.JHEP.2015.01.026
P577
2015-01-31T00:00:00Z